CNBX Pharmaceuticals Inc. (8C80.MU)

3.8765 0.0000 (0.00%) As of 05:56PM CEST. Market open.

CNBX Pharmaceuticals Inc.

#3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
United States
877 424 2429
https://www.cnbxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gabriel Yariv	President, COO & Executive Chairman	247.95k	N/A	1976
Mr. Eyal Barad	Co-Founder, CEO & Director	254.78k	N/A	1965
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA	Chief Financial Officer	71.3k	N/A	1970
Dr. Sanja Goldberg	Chief Technology Officer	45.55k	N/A	1976
Noam Permont	Vice President of Public Relations & Investor Relations	N/A	N/A	N/A
Dr. Sigalit Ariely-Portnoy Ph.D.	Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board	N/A	N/A	1964
Dr. Tal Mofkadi Ph.D.	Financial Advisor & Member of Advisory Board	N/A	N/A	N/A
Mr. Yasha Borstein	Chief Data Officer	N/A	N/A	1963
Dr. Yaakov Waksman	Head of Cannabidiol Research	N/A	N/A	1952
Dr. Ilya Reznik M.D.	Head of Neuropsychiatry Development	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.

Corporate governance

CNBX Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.